![Omar Khalil](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Omar Khalil
Direktor/Vorstandsmitglied bei
Solu Therapeutics
Profil
Omar Khalil is currently Managing Director at SHVMS, LLC since 2024.
Mr. Khalil is Director at Geneos Therapeutics, Inc. since 2023.
Mr. Khalil is Director at Kestrel Therapeutics, Inc. since 2022.
Mr. Khalil is Director at Solu Therapeutics, Inc. since 2023.
Mr. Khalil is Board Member at MycRX since 2021.
Former roles include Vice President & US Hospital Products at Baxter International, Inc. from 2015 to 2017, Vice President & General Manager at Kaleo, Inc. from 2017 to 2020, and Principal at McKinsey & Co., Inc. Education includes undergraduate and graduate degrees from the University of Michigan.
Aktive Positionen von Omar Khalil
| Unternehmen | Position | Beginn |
|---|---|---|
SHVMS, LLC
 SHVMS, LLC Investment ManagersFinance Sante Ventures invests in companies located in the United States. The firm targets companies operating in the fields of medical technologies, biotechnology, healthcare services and healthcare IT. It provides financing for seed and early-stage capital requirements. | Private Equity Investor | 01.01.2020 |
Kestrel Therapeutics, Inc.
 Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology development company | Direktor/Vorstandsmitglied | 01.01.2022 |
Solu Therapeutics
 Solu Therapeutics BiotechnologyHealth Technology Operates as a biotechnology that develops therapeutics to eliminate disease-driving cells in cancer, immunology and autoimmunity | Direktor/Vorstandsmitglied | 01.01.2023 |
MycRx
 MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Direktor/Vorstandsmitglied | 01.01.2021 |
Geneos Therapeutics, Inc.
 Geneos Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes neo-antigen based personalized cancer therapies | Direktor/Vorstandsmitglied | 01.01.2023 |
Ehemalige bekannte Positionen von Omar Khalil
| Unternehmen | Position | Ende |
|---|---|---|
Kaleo, Inc.
 Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Develops drug or device combination products | Private Equity Investor | 01.01.2020 |
| BAXTER INTERNATIONAL INC. | Corporate Officer/Principal | 01.01.2017 |
McKinsey & Co., Inc.
 McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Corporate Officer/Principal | - |
Ausbildung von Omar Khalil
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
37
Beziehungen ersten Grades
9
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 9 |
|---|---|
Baxter International, Inc.
 Baxter International, Inc. Medical SpecialtiesHealth Technology Produces and supplies medical products, healthcare systems, therapies and pharmaceuticals & provide kidney care services | Health Technology |
Kaleo, Inc.
Kaleo, Inc. Pharmaceuticals: MajorHealth Technology Develops drug or device combination products | Health Technology |
McKinsey & Co., Inc.
McKinsey & Co., Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a management consulting firm | Commercial Services |
University of Michigan
 University of Michigan Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
SHVMS, LLC
SHVMS, LLC Investment ManagersFinance Sante Ventures invests in companies located in the United States. The firm targets companies operating in the fields of medical technologies, biotechnology, healthcare services and healthcare IT. It provides financing for seed and early-stage capital requirements. | Finance |
Geneos Therapeutics, Inc.
Geneos Therapeutics, Inc. BiotechnologyHealth Technology Develops and commercializes neo-antigen based personalized cancer therapies | Health Technology |
Kestrel Therapeutics, Inc.
Kestrel Therapeutics, Inc. Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology development company | Commercial Services |
MycRx
MycRx Miscellaneous Commercial ServicesCommercial Services Operates as a biotechnology company that develops small molecule inhibitors of the Myc oncoprotein | Commercial Services |
Solu Therapeutics
Solu Therapeutics BiotechnologyHealth Technology Operates as a biotechnology that develops therapeutics to eliminate disease-driving cells in cancer, immunology and autoimmunity | Health Technology |
